Australia-based Bionomics has revealed that further data analysis of its phase two post-traumatic stress disorder (PTSD) trial indicated the potential for significant patient benefit when drug exposure is adequate, it was reported yesterday.
Additional work conducted on a drug exposure-response analysis indicated a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at 12 weeks. Presently, the product is in phase two trial to treat agitation and is a negative allosteric modulator of the alpha-7 (alpha-7) nicotinic acetylcholine receptor.
International pharmacometrics consulting firm, Pharmetheus, conducted an additional data analysis, which indicated a statistically significant response when drug exposure versus response was measured in the phase two trial or Restore trial. According to the company, the analysis indicated a decrease in total PTSD symptoms as measured by total CAPS-5, the endpoint mandated by the US Food & Drug Administration (FDA) for PTSD trials. The analysis quantified the level of efficacy of BNC210 on the overall CAPS-5 score linked to exposure (blood levels) of BNC210.
Bionomics is awaiting guidance from the FDA on the next steps for BNC210 for PTSD, including the design of a further trial and whether BNC210 is eligible for fast track designation.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT